Risk Partners Life Sciences Roundtable 2025, thank you very much! 

Risk Partners on Going Public and the capital market blog on prospectus liability
insurance

Over the past few months, we have expanded our expertise in the Prospectus liability insurance with a broad audience on two renowned platforms. Here is an overview:

  • Kapitalmarkt.blog
    In the article "POSI insurance - the protective vest on the capital market", we explain why prospectus liability insurance is an indispensable tool for companies that are active on the capital market. The article shows in a practical way how such insurance not only minimizes liability risks, but also strengthens investor confidence.

  • GoingPublic Magazine
    In "Liability risks in uplisting and private placements", we focus on the particular risks that arise in private placements and the switch to regulated market segments. Here, too, we emphasize how well thought-out prospectus liability insurance can create the necessary security for issuers.

From our projects and the special features of POSI and D&O insurance as claims-made insurances, we know how important it is to have such an insurance program ideally in place. 24 months in advance structure. It is therefore important for us to share our knowledge and expertise so that companies are optimally prepared for the challenges.

🔍 How can we help you? Whether you are planning an IPO, preparing a private placement or want to protect your company against potential liability risks: We provide you with comprehensive advice on Prospectus liability insurance and develop the optimum solution for your requirements.

👉 Get in touch with us today!

Also read our other blog posts

Being Public

Public prosecutor's office investigates: Suspicion of deception in short-time work (Sono Motors)

No startup bonus for criminal and administrative offenses. The incident and possible insurance cover. As exclusively researched by Hannah Schwär and her team at Capital Magazin, the founders of Sono Motors are now also facing problems with the public prosecutor's office. According to Capital Magazin, subsidy fraud in the context of short-time work and the programs surrounding the corona crisis is in the offing. The company, which is listed on the NASDAQ via De-SPAC, has already filed a report with the SEC. While the loss amount of EUR 40,000 is still being

Read more "
Life Sciences

Atrialis GmbH - experts in clinical trial insurance

Atrialis GmbH - experts in clinical trial insurance & Risk Partners will play in the same team in the future. LifeSciences - Leading risk concepts for leading science! Under this guiding principle, we have been able to advise innovative companies from the biotechnology, pharmaceutical and medical device sectors comprehensively on risk issues for many years and support them with suitable insurance solutions in all growth and study phases, from foundation to IPO and beyond (e.g. insuring a clinical trial). Together with my team at Risk Partners GmbH, we would like to continue our focus, our passion

Read more "
Being Public

"I believe in a strong IPO comeback in 2024" - Interview Platform Life Sciences

Risk Partners in the trade press. Florian was approached by the journalists from Plattform Life Sciences for an interview on our view of 2024 and the development of Risk Partners over the past year. In addition to challenging claims, product innovations (e.g. all about POSI insurance) from Risk Partners, Florian also discusses our motives for the "team up" with the fantastic colleagues from Atrialis GmbH - experts in clinical trials. Click here for Florian's interview. Read the interview

Read more "
4 pillars of cyber insurance for venture capital and private equity
Cyber Security

Cyber insurance Venture capital and private equity

Why cyber insurance does not transfer the core risk of VC & PE funds and why we have invested in Risk Partners cyber master agreements. Why cyber risks are relevant for venture capital and private equity funds With the increasing growth of the cyber crime industry (see Federal Office for the Protection of the Constitution), venture capital (VC) and private equity (PE) funds and their fund managers are also increasingly exposed to cyber risks. For years, this has been reflected in the claims we have been able to support, in which fund managers have ranked first year after year among the industries we advise.

Read more "
Being Public

Whistleblower Protection Act

Whistleblower Protection Act ... is now in force. Hey #VCs, do you already have a system in place for safe #whistleblowing? And what about insurance cover in your D&O insurance? One month ago today, the German Whistleblower Protection Act came into force. Since July 2, 2023, not only companies with more than 50 employees, but also fund managers or ManCos (capital management companies pursuant to Section 17 (1) of the German Investment Code) are obliged to set up and operate a whistleblower system, regardless (!) of the number of employees. As of December 2

Read more "
Life Sciences

St. Gallen study: USD 6 billion per drug

HSG St. Gallen: Drug costs USD 6.16 billion on average. Are the days of new drugs costing less than USD 1 billion over? There were figures in the industry that spoke of USD 700-1,000 million as the cost of developing a new drug. A study by the University of St. Gallen covering the period 2001-2020 found that the cost of developing new drugs has risen dramatically. It was estimated that the cost of developing a new drug now stands at

Read more "